Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on nets $54mm for Durata

Executive Summary

Durata Therapeutics Inc. (developing drugs for infectious diseases) netted $54mm through the follow-on public offering of 8.22mm common shares (including the overallotment) at $7 each. The company will use the funds to gain US and EU marketing approval for its lead antibiotic dalbavancin, for its scale-up manufacturing, and to pursue other indications for the compound.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies